Avidity Partners Takes 5.1% Stake in Dianthus Therapeutics
Ticker: DNTH · Form: SC 13D · Filed: Jan 31, 2024 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | SC 13D |
| Filed Date | Jan 31, 2024 |
| Risk Level | medium |
| Pages | 14 |
| Reading Time | 16 min |
| Key Dollar Amounts | $0.001, $5.09 |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: insider-ownership, activist-investing, stake-disclosure
TL;DR
**Avidity Partners just revealed a 5.1% stake in Dianthus, signaling potential activist moves.**
AI Summary
Avidity Partners Management LP, a Dallas-based investment firm, has filed an SC 13D, indicating they now beneficially own 5.1% of Dianthus Therapeutics, Inc.'s common stock as of January 22, 2024. This filing signals that Avidity Partners may seek to influence the management or direction of Dianthus Therapeutics, moving beyond a passive investment. For current or prospective shareholders, this could mean potential strategic changes or increased scrutiny on the company's operations, which might impact stock performance.
Why It Matters
A significant stake by an activist investor like Avidity Partners could lead to strategic shifts at Dianthus Therapeutics, potentially affecting its future value and operational focus.
Risk Assessment
Risk Level: medium — The filing indicates a potential for Avidity Partners to influence company strategy, which could be positive or negative depending on their intentions and execution.
Analyst Insight
A smart investor would monitor future filings and news from both Avidity Partners and Dianthus Therapeutics for any indications of strategic changes or activist demands, as this could significantly impact the stock's trajectory.
Key Numbers
- 5.1% — Beneficial Ownership (Percentage of Dianthus Therapeutics' common stock owned by Avidity Partners Management LP)
- January 22, 2024 — Date of Event (The date that triggered the requirement for this SC 13D filing)
- 252828108 — CUSIP Number (Identifier for Dianthus Therapeutics' Common Stock)
Key Players & Entities
- Avidity Partners Management LP (company) — filer and beneficial owner of Dianthus Therapeutics stock
- Dianthus Therapeutics, Inc. /DE/ (company) — subject company whose stock was acquired
- Dee Raibourn, Esq. (person) — person authorized to receive notice for Avidity Partners Management LP
- Dallas, Texas (location) — business location of Avidity Partners Management LP
- Cambridge, MA (location) — business location of Dianthus Therapeutics, Inc.
Forward-Looking Statements
- Avidity Partners Management LP will engage with Dianthus Therapeutics' management to discuss strategic initiatives. (Avidity Partners Management LP) — medium confidence, target: Within 6-12 months
- Dianthus Therapeutics' stock price may experience increased volatility due to the activist stake. (Dianthus Therapeutics, Inc. /DE/) — medium confidence, target: Near-term (1-3 months)
FAQ
Who filed this SC 13D statement?
The SC 13D statement was filed by Avidity Partners Management LP, located at 2828 N Harwood Street, Suite 1220, Dallas, Texas 75201.
What company's stock is the subject of this filing?
The subject company is Dianthus Therapeutics, Inc. /DE/, with its business address at 300 Technology Square, 8th Floor, Cambridge, MA 02139.
What percentage of Dianthus Therapeutics' common stock does Avidity Partners Management LP beneficially own?
Avidity Partners Management LP beneficially owns 5.1% of the common stock of Dianthus Therapeutics, Inc.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was January 22, 2024.
Why is an SC 13D filing significant compared to a 13G?
An SC 13D filing indicates that the reporting person, in this case Avidity Partners Management LP, has acquired more than 5% of a company's stock with the intent to influence or control the company, rather than just holding it as a passive investment, which would typically be reported on a 13G.
Filing Stats: 4,105 words · 16 min read · ~14 pages · Grade level 16.7 · Accepted 2024-01-31 12:11:40
Key Financial Figures
- $0.001 — tice and Communications) Common Stock, $0.001 par value (Title of Class of Securiti
- $5.09 — the OpCo at a weighted average price of $5.09 per share. At the effective time of the
Filing Documents
- d10944180_13d.htm (SC 13D) — 133KB
- 0000919574-24-000598.txt ( ) — 135KB
(a)
Item 1(a) Security and Issuer. Common stock, $0.001 par value of Dianthus Therapeutics, Inc. (the “Issuer”)
(b)
Item 1(b) Address of Issuer’s Principal Executive Offices. 7 Times Square, 43 rd Floor, New York, New York 10036
(a)
Item 2(a) Name of Person Filing. This statement is filed on behalf of each of the following person (collectively, the “Reporting Persons”): i. Avidity Partners Management LP; ii. Avidity Partners Management (GP) LLC; iii. Avidity Capital Partners Fund (GP) LP; iv. Avidity Capital Partners (GP) LLC; v. Avidity Master Fund LP; vi. Avidity Private Master Fund I LP; vii. David Witzke; and viii. Michael Gregory. The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to a Reporting Persons is made by such Reporting Persons. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein. The Reporting Persons have entered into a joint filing agreement, filed as Exhibit A to this Schedule 13D, pursuant to which the Reporting Persons agreed to file the Schedule 13D and any amendments thereto in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
(b)
Item 2(b) Address of Principal Business Office. The address of the principal business office of each of the Reporting Persons is 2828 N Harwood Street, Suite 1220, Dallas, Texas 75201.
(c)
Item 2(c) The principal business of Avidity Partners Management LP is managing investments. Avidity Partners Management (GP) LLC is the general partner of Avidity Partners Management LP. Avidity Capital Partners Fund (GP) LP serves as the general partner of private investment funds managed by Avidity Partners Management LP, including Avidity Master Fund LP and Avidity Private Master Fund I LP. Avidity Capital Partners (GP) LLC is the general partner of Avidity Capital Partners Fund (GP) LP. Messrs. Witzke and Gregory are the managing members of Avidity Partners Management (GP) LLC and Avidity Capital Partners (GP) LLC.
(d)
Item 2(d) None of the Reporting Persons have been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
(e)
Item 2(e) None of the Reporting Persons has been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction resulting in any judgment, decree or final order enjoining them from engaging in future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.
(f)
Item 2(f) Citizenship. i. Avidity Partners Management LP is a Delaware limited partnership; ii. Avidity Partners Management (GP) LLC is a Delaware limited liability company; iii. Avidity Capital Partners Fund (GP) LP is a Delaware limited partnership; iv. Avidity Capital Partners (GP) LLC is a Delaware limited liability company; v. Avidity Master Fund LP is a Cayman Islands exempted limited partnership; vi. Avidity Private Master Fund I LP is a Cayman Islands exempted limited partnership; vii. David Witzke is a citizen of the United States of America; and viii. Michael Gregory is a citizen of the United States of America. Item 3 Source and Amount of Funds or Other Consideration. The funds used for the acquisition of the Common Stock and warrants to purchase Common Stock reported herein came from the working capital of private funds advised by Avidity Partners Management LP. On September 11, 2023, pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated May 2, 2023, by and among the Issuer, Dio Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and Dianthus Therapeutics OpCo, Inc. (formerly Dianthus Therapeutics, Inc.), a Delaware corporation (“OpCo”), among other matters, Merger Sub merged with and into OpCo, with OpCo surviving as a wholly owned subsidiary of the Company (the “Merger”). In connection with the completion of the Merger, the Company changed its name from “Magenta Therapeutics, Inc.” to “Dianthus Therapeutics, Inc.” The Issuer offered further shares of Common Stock and Pre-Funded Warrants in a private placement transaction on January 22, 2024 (the “Private Placement”). The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which was filed as Exhibit 2.1 to the Issuer’